More patients receiving asciminib than investigator-selected tyrosine kinase inhibitor had major molecular response at 48 weeks<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, June 5, 2024 (HealthDay News) — For patients with newly diagnosed chronic myeloid leukemia (CML), asciminib shows superior efficacy and a favorable safety profile compared with investigator-selected tyrosine kinase inhibitors (TKIs), according to a study published online May 31 in the New England Journal of Medicine<\/em> to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.<\/p>\n Andreas Hochhaus, Dr.Med., from Universit \u00a4tsklinikum Jena and Comprehensive Cancer Center Central Germany, and colleagues randomly assigned patients with newly diagnosed CML to receive asciminib or an investigator-selected TKI (including imatinib and second-generation TKIs) in a 1:1 ratio (201 and 204 patients, respectively). Patients were followed for a median of 16.3 and 15.7 months in the asciminib and investigator-selected TKI groups, respectively.<\/p>\n The researchers found that at week 48, a major molecular response occurred in 67.7 and 49.0 percent of patients in the asciminib and investigator-selected TKI group, respectively; within the imatinib stratum, a major molecular response occurred in 69.3 and 40.2 percent of those in the asciminib and imatinib groups, respectively, while in the second-generation TKI stratum, the corresponding percentages were 66.0 and 57.8 percent with asciminib and TKIs. Compared with imatinib and second-generation TKIs, adverse events of grade 3 and higher and events leading to discontinuation of the trial regimen occurred less often with asciminib.<\/p>\n “Long-term follow-up is needed to further elucidate the benefit of asciminib as a treatment for newly diagnosed CML,” the authors write. “Currently, after a median follow-up of almost 1.5 years, asciminib has had superior efficacy and favorable safety and side-effect profiles as compared with investigator-selected TKIs and with imatinib in patients with newly diagnosed CML.”<\/p>\n Several authors disclosed ties to pharmaceutical companies, including Novartis, which manufactures asciminib and funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n